ストックスクリーナーアプリを入手
271.94
1.98%
-5.50
プレマーケット:
270.97
-0.97
-0.36%
前日終値:
$277.44
開ける：
$275.64
24時間の取引高:
1.44M
Relative Volume:
1.63
時価総額：
$39.87B
収益：
$5.02B
当期純損益:
$1.31B
株価収益率:
30.52
EPS:
8.91
ネットキャッシュフロー:
$1.56B
1週間 パフォーマンス:
-0.57%
1か月 パフォーマンス:
+5.40%
6か月 パフォーマンス:
+15.14%
1年 パフォーマンス:
+27.52%
1日の値動き範囲:
$271.94
$277.30
1週間の範囲:
$270.87
$278.86
52週間の値動き範囲:
$199.92
$278.86
Resmed Inc Stock (RMD) Company Profile
RMD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
271.94 | 40.68B | 5.02B | 1.31B | 1.56B | 8.91 |
|
ISRG
Intuitive Surgical Inc
|
481.09 | 179.42B | 9.15B | 2.61B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
178.25 | 52.03B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
87.55 | 44.11B | 9.93B | 1.12B | 1.58B | 2.25 |
|
WST
West Pharmaceutical Services Inc
|
239.26 | 17.92B | 2.90B | 467.20M | 306.90M | 6.37 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-15 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | 開始されました | Morgan Stanley | Overweight |
| 2025-01-16 | 開始されました | Goldman | Buy |
| 2025-01-10 | 開始されました | Piper Sandler | Neutral |
| 2024-12-13 | 開始されました | Stifel | Hold |
| 2024-09-24 | 開始されました | Robert W. Baird | Outperform |
| 2024-09-18 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | ダウングレード | Needham | Buy → Hold |
| 2024-06-25 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-06-24 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-02-06 | 再開されました | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-09-29 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | アップグレード | Needham | Hold → Buy |
| 2023-09-05 | ダウングレード | UBS | Buy → Neutral |
| 2023-08-01 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | 開始されました | UBS | Buy |
| 2023-04-14 | 開始されました | Mizuho | Buy |
| 2023-01-17 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-10-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-10-20 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-10-12 | 開始されました | Jefferies | Hold |
| 2022-09-08 | アップグレード | Citigroup | Neutral → Buy |
| 2022-08-15 | ダウングレード | CLSA | Buy → Outperform |
| 2022-08-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-08-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-08-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | 開始されました | Wolfe Research | Outperform |
| 2022-01-31 | アップグレード | Citigroup | Neutral → Buy |
| 2022-01-31 | アップグレード | Goldman | Neutral → Buy |
| 2022-01-28 | アップグレード | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-01-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-01-13 | アップグレード | CLSA | Outperform → Buy |
| 2022-01-13 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | アップグレード | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | アップグレード | Macquarie | Neutral → Outperform |
| 2021-10-22 | アップグレード | CLSA | Underperform → Outperform |
| 2021-08-02 | ダウングレード | CLSA | Outperform → Sell |
| 2021-08-02 | ダウングレード | Needham | Buy → Hold |
| 2021-07-28 | アップグレード | Jefferies | Underperform → Hold |
| 2021-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-07-14 | 開始されました | RBC Capital Mkts | Underperform |
| 2021-06-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-06-22 | アップグレード | Macquarie | Neutral → Outperform |
| 2021-06-22 | 開始されました | Robert W. Baird | Neutral |
| 2021-06-21 | 繰り返されました | Needham | Buy |
| 2021-06-16 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2021-06-09 | アップグレード | CLSA | Sell → Outperform |
| 2021-05-21 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-05-11 | アップグレード | Citigroup | Neutral → Buy |
| 2021-04-30 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-03-16 | アップグレード | Needham | Hold → Buy |
| 2020-11-02 | アップグレード | UBS | Neutral → Buy |
| 2020-10-30 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-10-27 | アップグレード | BofA Securities | Underperform → Neutral |
| 2020-08-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-05-01 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-02-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | 開始されました | CLSA | Underperform |
| 2020-01-31 | ダウングレード | UBS | Buy → Neutral |
| 2020-01-10 | 開始されました | Oppenheimer | Perform |
| 2019-11-22 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | アップグレード | UBS | Neutral → Buy |
| 2019-07-16 | ダウングレード | UBS | Buy → Neutral |
| 2019-05-06 | アップグレード | UBS | Neutral → Buy |
| 2019-04-18 | アップグレード | JP Morgan | Underweight → Neutral |
| 2019-01-25 | ダウングレード | Goldman | Buy → Neutral |
| 2019-01-25 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-10-26 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | 開始されました | Goldman | Buy |
すべてを表示
Resmed Inc (RMD) 最新ニュース
ResMed Inc (RMD) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Acquisitions - Yahoo.co
Global demand helps push ResMed shares to record high - inkl
Resmed Inc. Reports Strong Q4 2025 Earnings Growth - TipRanks
Resmed Australia shares hit record high on strong earnings - Investing.com
Resmed Australia shares hit record high on strong earnings By Investing.com - Investing.com India
Why Capstone Copper, Flight Centre, ResMed, and SKS shares are pushing higher today - The Motley Fool Australia
ResMed outlines 61%–63% gross margin target for FY26 while ramping up share buybacks and dividend - MSN
ResMed: Result 2025 - intelligentinvestor.com.au
ResMed's ASX shares hit record on earnings beat, but is the future still bright? - Livewire Markets
ResMed: Fiscal Q4 Earnings Snapshot - Norwalk Hour
ResMed Inc. 2025 Q2ResultsEarnings Call Presentation (NYSE:RMD) - Seeking Alpha
Resmed posts Wall Street beat in Q2 - MassDevice
ResMed share price hits record high on strong FY25 results - The Motley Fool Australia
ResMed Q4 Earnings: Key Metrics Highlight Revenue and EPS Growth - AInvest
ResMed Q4 FY2025 slides reveal 10% revenue growth, shift to net cash position By Investing.com - Investing.com South Africa
Here's What Key Metrics Tell Us About ResMed (RMD) Q4 Earnings - Yahoo Finance
Resmed Inc reports results for the quarter ended June 30Earnings Summary - TradingView
ResMed earnings beat by $0.07, revenue fell short of estimates - Investing.com Canada
ResMed (RMD) Surpasses Q4 Earnings and Revenue Estimates - Nasdaq
ResMed (NYSE:RMD) Surprises With Q2 Sales - Yahoo Finance
ResMed Reports Strong Q4 Earnings, Surpassing Wall Street ExpectationsNews and Statistics - IndexBox
Resmed Announces Increased Quarterly Dividend - TipRanks
Resmed beats quarterly profit estimates on strong demand for sleep devices - TradingView
ResMed Inc Reports Q4 Revenue of $1.3 Billion, Slightly Missing Estimates; EPS Growth of 23% - GuruFocus
Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025 - The Manila Times
RMD ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by ResMed Inc. - ACCESS Newswire
When is ResMed Inc. stock expected to show significant growthFree Stock Data Feed Backed By Experts - jammulinksnews.com
ResMed's 257th High-Volume Rank and Earnings Outlook Signal Strategic Short-Term Opportunities - AInvest
Spot Outliers Like ResMed Early with Money Flows - FXEmpire
ResMed Earnings Preview: Anticipating Growth Amidst Industry TrendsNews and Statistics - IndexBox
Stock Analysis | ResMed OutlookA Mixed Technical Picture Amid Strong Analyst Optimism - AInvest
Ozempic maker Novo Nordisk plunges 22%. What could this mean for Resmed shares? - The Motley Fool Australia
Will ResMed Inc. stock benefit from interest rate changesDay Trading Signals With High Precision Reviewed - metal.it
ResMed (RMD) To Report Earnings Tomorrow: Here Is What To Expect - Yahoo Finance
Calculating The Intrinsic Value Of ResMed Inc. (NYSE:RMD) - Yahoo.co
ResMed stock hits 52-week high at 275.86 USD By Investing.com - Investing.com Canada
ResMed stock hits 52-week high at 275.86 USD - Investing.com
ResMed Inc. Stock Poised for Technical ComebackTrade Scanner With Buy Zone Alerts Flagged - metal.it
How does ResMed Inc. compare to its industry peersBuild a diversified portfolio for risk management - jammulinksnews.com
What catalysts could drive ResMed Inc. stock higher in 2025Get exclusive market analysis for investors - jammulinksnews.com
What are analysts’ price targets for ResMed Inc. in the next 12 monthsPre Market Forecasts That Work - jammulinksnews.com
What is the dividend policy of ResMed Inc. stockRecord-breaking capital gains - jammulinksnews.com
Why ResMed Inc. stock attracts strong analyst attentionBig Profit Small Risk Alerts - metal.it
What makes ResMed Inc. stock price move sharplyAccess powerful market insights for free - jammulinksnews.com
Why is ResMed Inc. stock attracting strong analyst attentionTrack emerging stocks with high growth potential - jammulinksnews.com
Are Resmed CDI (ASX:RMD) shares good value in 2025? - Rask Media
Are Robust Financials Driving The Recent Rally In ResMed Inc.'s (NYSE:RMD) Stock? - 富途牛牛
What makes ResMed Inc. stock attractive to long term investorsVolume Spike Monitors - metal.it
Fisher & Paykel Healthcare (FPH AU) Vs. ResMed (RMD AU): Dislocation in Healthcare - Smartkarma
If You Invested $1000 in ResMed a Decade Ago, This is How Much It'd Be Worth Now - MSN
What drives ResMed Inc. stock priceFree Stock Selection - PrintWeekIndia
Resmed Inc (RMD) 財務データ
収益
当期純利益
現金流量
EPS
1.83%
2.83%
大文字化:
|
ボリューム (24 時間):